Last reviewed · How we verify
Xeris glucagon
Xeris glucagon is a Small molecule drug developed by Steven J. Russell, MD, PhD. It is currently in Phase 2 development.
Xeris glucagon is a glucagon receptor agonist, classified as an agonist drug. It is being studied for various conditions, including Type 1 diabetes, hypoglycemia, and post-bariatric hypoglycemia, in clinical trials involving artificial pancreas controllers.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Xeris glucagon |
|---|---|
| Sponsor | Steven J. Russell, MD, PhD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia (PHASE1, PHASE2)
- Three Way Crossover Closed Loop Study With Xeris Glucagon (PHASE1)
- The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas (NA)
- Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon (PHASE2, PHASE3)
- Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients (PHASE3)
- Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xeris glucagon CI brief — competitive landscape report
- Xeris glucagon updates RSS · CI watch RSS
- Steven J. Russell, MD, PhD portfolio CI
Frequently asked questions about Xeris glucagon
What is Xeris glucagon?
Who makes Xeris glucagon?
What development phase is Xeris glucagon in?
Related
- Manufacturer: Steven J. Russell, MD, PhD — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing